BioAtla
phase study design with | BioAtla
Company
Deck Type
Sector
Industry
Deck date
May 2023
Slide
18 of 44
Similar slides by BioAtla
See diffirences between slides (animation)
Investor Presentation
August 2023
phase study design with | BioAtla
Investor Presentation
November 2022
phase study design with in refractory patients | BioAtla
Investor Presentation
November 2022
phase study design with | BioAtla
Investor Presentation
August 2022
phase study design with in refractory patients | BioAtla
Related slides by other companies
Anebulo Pharmaceuticals
Investor Day
September 2022
phase part adaptive study design | Anebulo Pharmaceuticals
ATAI
Investor Presentation
January 2024
demonstrated safety level and plasma concentrations of in line with previous trials potential therapeutic plasma levels no serious adverse events reported asymptomatic prolongation phase study trial design results summary | ATAI
Erasca
Investor Presentation
November 2023
proposed pivotal phase trial designs creative strategy includes high randomized melanoma trial and tissue agnostic indication | Erasca
Dare Bioscience
Investor Presentation
August 2023
cream phase respond study overview | Dare Bioscience
Other recent decks by BioAtla
See all presentations (8 decks)
Investor Presentation
January 2024
Investor Presentation
August 2023
Investor Presentation
November 2022
Investor Presentation
August 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights